Argenx

85 articles with Argenx

• argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

  7/22/2021

  argenx announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET to discuss its half year 2021 financial results and provide a second quarter business update.

• argenx to Host Virtual R&D Day on July 20, 2021

  7/14/2021

  argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced that it will host a virtual R&D Day on Tuesday, July 20, 2021 at 3:00 p.m. CET to highlight its ‘argenx 2025 vision’ and provide an update of its immunology pipeline.

• 

  Argenx Regains Rights to Blood Cancer Drug Following Dropped $1.6 Billion Deal

  6/8/2021

  As a result of the termination, argenx will regain worldwide rights to cusatuzumab, its anti-CD70 antibody, from Cilag FmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• argenx to regain global rights to cusatuzumab

  6/7/2021

  argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced it will regain worldwide rights to its anti-CD70 antibody cusatuzumab from Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• 

  BioSpace Movers & Shakers, June 4

  6/4/2021

  Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.

• argenx to Present at Upcoming Investor Conferences - June 01, 2021

  6/1/2021

  argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced that members of management will participate in the following upcoming investor conferences:

• argenx Appoints Karl Gubitz as Chief Financial Officer

  6/1/2021

  argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced the appointment of Mr. Karl Gubitz as Chief Financial Officer.

• argenx announces results of Annual General Meeting of Shareholders - May 11, 2021

  5/11/2021

  argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced that the proposed resolutions presented at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed.

• argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021

  5/7/2021

  May 7, 2021 Breda, the Netherlands – argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced that it will host a conference call and audio webcast on Friday, May 14, 2021 at 2:30 p.m. CET to discuss its first quarter 2021 financial results and provide a business update.

• Elektrofi Enters Global Collaboration and License Agreement with argenx to Explore New Subcutaneous Product Formulations

  4/20/2021

  The agreement provides argenx access to Elektrofi’s breakthrough high-concentration, low-volume delivery technology for the development of therapeutic products

• 

  Biopharma Companies Entering 2021 With New Collabs, Partnerships

  1/8/2021

  Here’s a run-down of some of the most recent collaboration announcements this week.

• argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

  11/17/2020

  Created in partnership with Sarofsky Productions, A Mystery to Me explores how three people persevere through the challenges of living with myasthenia gravis, a rare neuromuscular disease

• Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology

  10/6/2020

  Halozyme Therapeutics, Inc. announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019.

• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
• 

  Argenx’s Myasthenia Gravis Drug Shows Positive Results in Late-Stage Trial

  5/26/2020

  MG is a rare and chronic autoimmune disease marked by IgG antibodies disrupting communication between nerves and muscles.

• Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

  5/22/2019

  Halozyme Therapeutics, Inc. announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.

• argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology

  2/4/2019

  argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn

• 

  Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million

  2/4/2019

  Argenx, based in Breda, the Netherlands, and Halozyme Therapeutics, headquartered in San Diego, CA, signed a global collaboration and license deal that lets Argenx use Halozyme’s Enhanze drug delivery technology to develop multiple products.
• 

  The 20 Hottest Pipeline Drugs to Watch in 2019

  1/3/2019

  EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.

• Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab

  12/3/2018

  Addition of investigational antibody cusatuzumab to robust oncology pipeline reflects Janssen's commitment to advance innovative therapies for blood cancers where unmet medical needs remain